ClinicalTrials.gg
Active, not recruitingNCT07639021Updated Sep 16, 2026

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

A Phase 2 interventional study of NNC0662-0419 and Semaglutide in Obesity, sponsored by Novo Nordisk A/S. Active, not recruiting at 25 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
233
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 207 studies in Obesity by Novo Nordisk A/S — 48 open to participants now, 66 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.

Enrollment
66th of 166
233 · median 138
Started
2026
with 46 others
Phase 2
13 of 207
1 open now
Primary completion
2027-06
later than 22 of 65 live
Registered
186th of 207
by date

Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 66th largest by enrollment of the 166 interventional ones that give a count, is one of 47 that started in 2026, is one of 13 in phase 2, reaches primary completion later than 22 of the 65 other live ones, and was the 186th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

48 of the 207 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

43 more — sign in →

By country, each count listing its studies:

All 48 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Obesity by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (sex assigned at birth, inclusive of all gender identities).
  • Age 18 years or above at the time of signing the .
  • (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m\^2) at screening.
  • Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to study intervention(s) or related products.
  • Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening.
  • (HbA1c) ≥ 6.5% (48 Millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes mellitus.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
233 participants (actual)

Study arms

  • Experimental
    NNC0662-0419

    Participants will receive NNC0662-0419 administered subcutaneously in a dose-escalation manner.

    Drug: NNC0662-0419

  • Placebo comparator
    NNC0662-0419 placebo

    Participants will receive NNC0662-0419 placebo administered subcutaneously in a dose-escalation manner.

    Drug: NNC0662-0419 Placebo

  • Experimental
    Semaglutide

    Participants will receive semaglutide administered subcutaneously in a dose-escalation manner.

    Drug: Semaglutide

  • Placebo comparator
    Semaglutide placebo

    Participants will receive semaglutide placebo administered subcutaneously in a dose-escalation manner.

    Drug: Semaglutide placebo

Interventions

  • NNC0662-0419 will be administered subcutaneously.

  • Semaglutide will be administered subcutaneously.

  • DrugNNC0662-0419 Placebo

    Placebo matched to NNC0662-0419 will be administered subcutaneously.

  • DrugSemaglutide placebo

    Placebo matched to semaglutide will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Number of gastrointestinal adverse events

    Measured as number of events.

    Time frame: From week 0 to week 39

Secondary outcomes

  1. Relative change in body weight

    Measured as percentage (%) change.

    Time frame: From week 0 to week 32

  2. Change in body mass index (BMI)

    Measured as kilogram per square meter (kg/m\^2).

    Time frame: From week 0 to week 32

07

Study locations

25 sites
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 12 months is close to that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2026
First posted
Jun 10, 2026
StartActual
Jun 9, 2026
Primary completionEst.
Jun 14, 2027
CompletionEst.
Jun 14, 2027
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07639021
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 10, 2026
Start date
Jun 9, 2026
Primary completion
Jun 14, 2027 (estimated)
Completion
Jun 14, 2027 (estimated)
Last update
Sep 16, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NNC0662-0419

Start the discussion